<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>dermatology research Archives - MoleMax Systems</title>
	<atom:link href="https://molemaxsystems.com/tag/dermatology-research/feed/" rel="self" type="application/rss+xml" />
	<link></link>
	<description>Provide the best skin imaging device</description>
	<lastBuildDate>Tue, 09 Jun 2026 00:41:12 +0000</lastBuildDate>
	<language>en-AU</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://molemaxsystems.com/wp-content/uploads/2020/10/favicon.png</url>
	<title>dermatology research Archives - MoleMax Systems</title>
	<link></link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Global Skin Cancer Burden From 1990 to 2023 and Projection to 2050</title>
		<link>https://molemaxsystems.com/global-skin-cancer-burden-from-1990-to-2023-and-projection-to-2050/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 09 Jun 2026 00:33:36 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[dermatology research]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=9963</guid>

					<description><![CDATA[<p>ALLDIGITAL DERMOSCOPY &AMP; SKIN IMAGINGEVIDENCE &AMP; RESEARCHMOLE MAPPING &AMP; LESION TRACKINGUNCATEGORISED</p>
<p>The post <a href="https://molemaxsystems.com/global-skin-cancer-burden-from-1990-to-2023-and-projection-to-2050/">Global Skin Cancer Burden From 1990 to 2023 and Projection to 2050</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[
		<div id="fws_6a3f659e6c18a"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row top-level"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<nav role="none"><span class="wi-fullname brand-fg">Youyou Zhou, MD, PhD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Weiming Zhong, MD, PhD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Xulei Liu, MBBS; </span>Jianglin Zhang, MD, PhD</nav>
<p>&nbsp;</p>
<p>Malignant skin cancers impose an escalating and heterogeneous health burden worldwide.<sup>1</sup> Using the Global Burden of Disease (GBD) 2023 database,<sup>2</sup> we summarize these cancers’ epidemiology, subgroup patterns, and projections to 2050.</p>
<div class="h3 cb section-type-section ">
<h3 class="heading-text thm-col sb-sc"><strong>Methods</strong></h3>
</div>
<p class="para">We analyzed GBD 2023 estimates (1990-2023) for malignant melanoma, cutaneous squamous cell carcinoma, and basal cell carcinoma. Outcomes included prevalence and disability-adjusted life-years (DALYs; years of life lost due to premature death plus years lived with disability). Subgroup analyses were conducted by sex, age group, and Sociodemographic Index (SDI; range, 0-1), defined as the geometric mean of indices of fertility in those younger than 25 years, education among those aged 15 years and older, and lag-distributed income per capita. Projections to 2050 used a bayesian age-period-cohort (BAPC) model, a bayesian hierarchical framework that jointly estimates age, period, and cohort effects and provides uncertainty intervals. For basal cell carcinoma, we excluded the 2005 to 2009 surveillance-artifact period and fit projections using 2010 to 2023 data. Additional methods are provided in the eMethods in Supplement 1. This study was deemed to be not human participant research by Shenzhen People’s Hospital; therefore, institutional review board approval and informed consent were not required.</p>
<p>To read this article in full <a href="https://jamanetwork.com/journals/jamadermatology/fullarticle/2848888?guestAccessKey=2634ca35-bbf2-434d-972c-06ce8df175f5&amp;utm_medium=email&amp;utm_source=postup_jn&amp;utm_campaign=article_alert-jamadermatology&amp;utm_content=olf-tfl_&amp;utm_term=051326" target="_blank" rel="noopener">please click here</a>.</p>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/uncategorised-hi/">UNCATEGORISED</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/global-skin-cancer-burden-from-1990-to-2023-and-projection-to-2050/">Global Skin Cancer Burden From 1990 to 2023 and Projection to 2050</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Spontaneous Regression of Well-Differentiated Squamous Cell Skin Cancer Following Partial, Diagnostic Biopsy: Retrospective Cohort in Queensland</title>
		<link>https://molemaxsystems.com/spontaneous-regression-of-well-differentiated-squamous-cell-skin-cancer-following-partial-diagnostic-biopsy-retrospective-cohort-in-queensland/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 14 Apr 2026 00:44:00 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[dermatology research]]></category>
		<category><![CDATA[Squamous Cell Carcinoma]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=9575</guid>

					<description><![CDATA[<p>ALLDIGITAL DERMOSCOPY &AMP; SKIN IMAGINGEVIDENCE &AMP; RESEARCHMOLE MAPPING &AMP; LESION TRACKINGUNCATEGORISED</p>
<p>The post <a href="https://molemaxsystems.com/spontaneous-regression-of-well-differentiated-squamous-cell-skin-cancer-following-partial-diagnostic-biopsy-retrospective-cohort-in-queensland/">Spontaneous Regression of Well-Differentiated Squamous Cell Skin Cancer Following Partial, Diagnostic Biopsy: Retrospective Cohort in Queensland</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[
		<div id="fws_6a3f659e6e9f1"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<p><span class="name western">David Wilkinson</span>, <span class="name western">Julia Sottovia</span>, <span class="name western">Sonje Hoogstad</span></p>
<h2 data-anchor-id="abstract1">Abstract</h2>
<section id="sec1">
<h3 class="pmc_sec_title"><strong>Introduction</strong></h3>
<p>Well-differentiated squamous cell skin cancer (WDSCC) is common in sun-exposed populations. Guidelines promote active treatment, with excision preferred. Isolated cases of spontaneous regression (SR) have been reported. Having observed multiple patients with apparent SR following partial, diagnostic biopsy, we did a retrospective cohort study to explore this further.</p>
</section>
<section id="sec2">
<h3 class="pmc_sec_title"><strong>Objectives</strong></h3>
<p>We sought to report frequency of SR of WDSCC following partial biopsy by a general practitioner (GP) in a primary care setting and referral to a public hospital general surgery service for excision, to report patient characteristics, and to estimate the time interval between biopsy and SR.</p>
</section>
<section id="sec3">
<h3 class="pmc_sec_title"><strong>Methods</strong></h3>
<p>Retrospective cohort study (22 months) of patients in Queensland, Australia, with a diagnosis of WD-SCC following a partial biopsy by a GP. SR was defined as no clinical or dermoscopy evidence of squamous cell carcinoma (SCC).</p>
</section>
<section id="sec4">
<h3 class="pmc_sec_title"><strong>Results</strong></h3>
<p>Among 153 consecutive patients with WDSCC referred for excision, 51 showed SR at consultation (33.3%, 95% CI: 25.6–41). There was no significant difference in age or sex of the SR and non-SR groups. In almost all patients with SR (N=49, 96.1%), lesions were located below the knee, compared with 90 (88.2%, <em>P</em>=0.042) without SR. Average interval between biopsy and surgical consultation was 13.6 weeks (range 2.7–24.7 weeks).</p>
</section>
<section id="sec5">
<h3 class="pmc_sec_title"><strong>Conclusions</strong></h3>
<p>WDSCC may spontaneously resolve following partial, diagnostic biopsy more often than previously reported. These preliminary observations may have implications for treatment options, especially among frail patients with comorbidities.</p>
<p>For information on the full article <a href="https://dpcj.org/index.php/dpc/article/view/5632/3252" target="_blank" rel="noopener">please click here</a>.</p>
</section>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/uncategorised-hi/">UNCATEGORISED</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/spontaneous-regression-of-well-differentiated-squamous-cell-skin-cancer-following-partial-diagnostic-biopsy-retrospective-cohort-in-queensland/">Spontaneous Regression of Well-Differentiated Squamous Cell Skin Cancer Following Partial, Diagnostic Biopsy: Retrospective Cohort in Queensland</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Dermoscopic Features of Acral Palmoplantar Nevi: Age and Site Correlation in a North African Cohort</title>
		<link>https://molemaxsystems.com/dermoscopic-features-of-acral-palmoplantar-nevi-age-and-site-correlation-in-a-north-african-cohort/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Thu, 08 Jan 2026 00:20:17 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[dermatology research]]></category>
		<category><![CDATA[Dermatoscope benefits]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=8963</guid>

					<description><![CDATA[<p>ALLDIGITAL DERMOSCOPY &AMP; SKIN IMAGINGEVIDENCE &AMP; RESEARCHMOLE MAPPING &AMP; LESION TRACKINGUNCATEGORISED</p>
<p>The post <a href="https://molemaxsystems.com/dermoscopic-features-of-acral-palmoplantar-nevi-age-and-site-correlation-in-a-north-african-cohort/">Dermoscopic Features of Acral Palmoplantar Nevi: Age and Site Correlation in a North African Cohort</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[
		<div id="fws_6a3f659e712fe"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<p>Meryem Soughi, Oumaima Bouraqqadi, Zakia Douhi, Sara Elloudi, Hanane Baybay, Fatimazahra Mernissi</p>
<h3><strong>ABSTRACT</strong></h3>
<p><strong>Introduction</strong>: Palmoplantar nevi (PPN) are common and sometimes difficult to diagnose because<br />
of their unusual clinical, dermoscopic, and histological features, often mistaken for acral lentiginous<br />
melanoma.</p>
<p><strong>Objective</strong>: This study aimed to investigate the different dermoscopic patterns of palmoplantar nevi<br />
and their correlation with age and location.</p>
<p><strong>Methods</strong>: This was a retrospective-prospective cohort study of a sample of the Moroccan population<br />
collected over 2 years. The diagnosis was based mainly on clinical and dermoscopic evaluation, and a<br />
biopsy performed in a single patient.</p>
<p><strong>Results</strong>: A total of 140 patients with 144 PPNs were included in this study. PPNs were more frequently<br />
located on the palms (64%) than on the soles (36%). The parallel furrow pattern (PFP) was the most<br />
frequent in 44% of patients, followed by the lattice pattern (17,4%), then the homogeneous pattern<br />
(16.7%), the fibrillar pattern (10,4%), the compound pattern (7%), the globular pattern (2 %), the<br />
dotted pattern (2 %), and finally, the atypical pattern (0.7%). We found a correlation between fibrillar<br />
and globular patterns with younger patients (P &lt;0.05) lattice pattern with pressure-free regions such<br />
as the arch and palmar region. In contrast, the fibrillar pattern was associated with heels and PFP with<br />
digital location.</p>
<p><strong>Conclusion</strong>: Recognition of these patterns is crucial for accurate diagnosis and to avoid unnecessary<br />
excisions.</p>
<p>To read the full article please <a href="https://www.dpcj.org/index.php/dpc/article/view/5065" target="_blank" rel="noopener">click here</a>.</p>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/uncategorised-hi/">UNCATEGORISED</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/dermoscopic-features-of-acral-palmoplantar-nevi-age-and-site-correlation-in-a-north-african-cohort/">Dermoscopic Features of Acral Palmoplantar Nevi: Age and Site Correlation in a North African Cohort</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Nicotinamide for Skin Cancer Chemoprevention</title>
		<link>https://molemaxsystems.com/nicotinamide-for-skin-cancer-chemoprevention/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 06 Jan 2026 00:49:52 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[dermatology research]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=8925</guid>

					<description><![CDATA[<p>ALLDIGITAL DERMOSCOPY &AMP; SKIN IMAGINGEVIDENCE &AMP; RESEARCHMOLE MAPPING &AMP; LESION TRACKINGUNCATEGORISED</p>
<p>The post <a href="https://molemaxsystems.com/nicotinamide-for-skin-cancer-chemoprevention/">Nicotinamide for Skin Cancer Chemoprevention</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[
		<div id="fws_6a3f659e73d69"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<nav role="none"><span class="wi-fullname brand-fg">Kimberly F. Breglio, MD, DPhil</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Katlyn M. Knox, BA</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Jonathan Hwang, BS; </span><span class="wi-fullname brand-fg">Rachel Weiss, BS</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Kyle Maas, BS</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Siwei Zhang, PhD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Lydia Yao, MS</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Chris Madden, MD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Yaomin Xu, PhD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Rebecca I. Hartman, MD, MPH</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Lee Wheless, MD, PhD</span></nav>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
		<div id="fws_6a3f659e7492f"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<h3><strong><span class="heading-text thm-col h3 cb section-type-keyPoints decorated-hed sb-sc ">Key Points</span></strong></h3>
<p><strong>Question</strong><br />
Does nicotinamide supplementation prevent skin cancer development?</p>
<p><strong>Findings</strong><br />
In this retrospective study of 33 822 veterans, there was a decreased risk of 3 types of skin cancer associated with use of nicotinamide. The magnitude of reduction was associated with the number of skin cancers before nicotinamide use.</p>
<p><strong>Meaning</strong><br />
The results of this study suggest that use of nicotinamide is associated with a reduced risk of skin cancer development.</p>
<p>To read more on this article please <a href="https://jamanetwork.com/journals/jamadermatology/article-abstract/2838591?guestAccessKey=6322d137-7880-47b6-b03c-cdced6a243b1&amp;utm_medium=email&amp;utm_source=postup_jn&amp;utm_campaign=article_alert-jamadermatology&amp;utm_content=olf-recommended-tfl_&amp;utm_term=101525" target="_blank" rel="noopener">click here</a>.</p>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/uncategorised-hi/">UNCATEGORISED</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/nicotinamide-for-skin-cancer-chemoprevention/">Nicotinamide for Skin Cancer Chemoprevention</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>All Eyes on Dermoscopy: Features of Benign Conjunctival Melanocytic Lesions</title>
		<link>https://molemaxsystems.com/all-eyes-on-dermoscopy-features-of-benign-conjunctival-melanocytic-lesions/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 25 Nov 2025 00:11:34 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[dermatology research]]></category>
		<category><![CDATA[Dermatoscope benefits]]></category>
		<category><![CDATA[Melanocytic Lesion]]></category>
		<category><![CDATA[ocular]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=8787</guid>

					<description><![CDATA[<p>ALLDIGITAL DERMOSCOPY &AMP; SKIN IMAGINGEVIDENCE &AMP; RESEARCHMOLE MAPPING &AMP; LESION TRACKINGUNCATEGORISED</p>
<p>The post <a href="https://molemaxsystems.com/all-eyes-on-dermoscopy-features-of-benign-conjunctival-melanocytic-lesions/">All Eyes on Dermoscopy: Features of Benign Conjunctival Melanocytic Lesions</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[
		<div id="fws_6a3f659e76e08"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<h3 class="_label"><strong>Abstract</strong></h3>
<p><strong>Introduction</strong>: Conjunctival nevi (CN) represent the majority of benign conjunctival melanocytic lesions (CML), followed by complexion-associated melanosis (CAM). Noninvasive methods like dermoscopy could be of importance to increase diagnostic accuracy in this biopsy-sensitive area. Because of the unique anatomy of the conjunctiva, dermoscopic findings differ significantly compared to the skin or other mucosae.</p>
<p><strong>Objective</strong>: Our objective was to analyze epidemiological, clinical, and dermoscopic characteristics of benign conjunctival melanocytic lesions and to explore their correlation to total body nevus count (TBNC).</p>
<p><strong>Methods</strong>: This retrospective study involved the collection and analysis of demographic data, patient information, and clinical and dermoscopic images from individuals with long-standing, stable, pigmented conjunctival lesions.</p>
<p><strong>Results</strong>: A total of 30 benign conjunctival melanocytic lesions in 28 patients (female/male :18/10) with a median age of 32 (range 16–68) years were evaluated. The prevalent dermoscopic pattern was a mixed, globular, homogeneous pattern (36.6%). Clear cysts were identified via dermoscopy in 60% of the lesions, and a reticular pattern was observed in all cases involving cysts (<em>P</em>&lt;0.05). The presence of benign CML was associated with a low TBNC (&lt;10) in 64.3%.</p>
<p><strong>Conclusions</strong>: The present study provides a detailed overview of the clinical and dermoscopic characteristics of benign CML. It highlights consistent patterns such as cyst-associated reticular features and a low TBNC among affected individuals. These findings support the clinical utility of dermoscopy as a noninvasive tool for differentiating between benign and suspicious conjunctival lesions. The observed association with low TBNC may warrant increased vigilance during ocular examination in patients with few cutaneous nevi. Prospective studies with larger cohorts are needed to confirm and extend these observations.</p>
<p>To read the full article <a href="https://dpcj.org/index.php/dpc/article/view/5596/3231" target="_blank" rel="noopener">please click here</a>.</p>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/uncategorised-hi/">UNCATEGORISED</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/all-eyes-on-dermoscopy-features-of-benign-conjunctival-melanocytic-lesions/">All Eyes on Dermoscopy: Features of Benign Conjunctival Melanocytic Lesions</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>A Diagnosis of Dysplastic Naevus has no Clinical Relevance and Unnecessarily Confounds Therapeutic Decision-Making</title>
		<link>https://molemaxsystems.com/a-diagnosis-of-dysplastic-naevus-has-no-clinical-relevance-and-unnecessarily-confounds-therapeutic-decision-making/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 16 Sep 2025 00:34:53 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[dermatology research]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=8345</guid>

					<description><![CDATA[<p>ALLDIGITAL DERMOSCOPY &AMP; SKIN IMAGINGEVIDENCE &AMP; RESEARCHMOLE MAPPING &AMP; LESION TRACKINGUNCATEGORISED</p>
<p>The post <a href="https://molemaxsystems.com/a-diagnosis-of-dysplastic-naevus-has-no-clinical-relevance-and-unnecessarily-confounds-therapeutic-decision-making/">A Diagnosis of Dysplastic Naevus has no Clinical Relevance and Unnecessarily Confounds Therapeutic Decision-Making</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[
		<div id="fws_6a3f659e79158"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<p><span class="accordion-tabbed__tab-mobile accordion__closed">Cliff Rosendahl,<span class="comma-separator"> </span></span><span class="accordion-tabbed__tab-mobile accordion__closed">Simon Clark<span class="comma-separator">, </span></span><span class="accordion-tabbed__tab-mobile accordion__closed">Syril Keena T. Que,<span class="comma-separator"> </span></span><span class="accordion-tabbed__tab-mobile accordion__closed">Denis Moir<span class="comma-separator">, </span></span><span class="accordion-tabbed__tab-mobile accordion__closed">Harald Kittler<span class="comma-separator">, </span></span><span class="accordion-tabbed__tab-mobile accordion__closed">Jane M. Grant-Kels</span></p>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
		<div id="fws_6a3f659e79c20"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<section id="section-1-en" class="article-section article-section__abstract" lang="en" data-lang="en">
<h2 id="d39388519" class="article-section__header section__title main abstractlang_en main">ABSTRACT</h2>
<div class="article-section__content en main">
<p>The term ‘dysplastic naevus’ first introduced in 1980, has since engendered considerable debate regarding its ontological legitimacy, the appropriateness of its nomenclature, and its potential prognostic significance. In this review, we undertake a critical examination of the extant literature, including a focus on the past decade. We will present case-based evidence elucidating how the persisting misdiagnosis of certain melanoma foci as dysplastic naevus, an interpretive approach adopted by many pathologists since 1980, has perpetuated the misconception that dysplastic naevi serve as definitive precursors to melanoma. We will also attempt to explain the persisting popularity of the diagnosis. We assert, based on current knowledge as detailed and explored in this review, that irrespective of whether it exists as a histological entity, and regardless of its persistence in practice, a diagnosis of dysplastic naevus by pathologists has no clinical relevance and that it does harm, by unnecessarily complicating the therapeutic decision-making role of clinicians.</p>
</div>
</section>
<section id="section-2-en" class="article-section article-section__abstract" lang="en" data-lang="en">
<h2 id="d39388532" class="article-section__header section__title highlights abstractlang_en highlights">Summary</h2>
<div class="article-section__content en highlights">
<ul class="unordered-list">
<li><b>Why was the study undertaken?</b> – Since 1980, the entity ‘dysplastic naevus’ has been frequently reported by dermatopathologists with the commonly communicated assumption that it is an intermediate lesion between naevus and melanoma. In the last 10 years, there have been significant advances in knowledge which refute this implication. Despite this, genomic research into its status continues, as does its influence on patient management.</li>
<li><b>What does this study add?</b> – Diagnostic accuracy in reporting subtypes of melanocytic lesions has been shown to be neither reliable nor reproducible. Regardless of this, it is now known that a melanoma-associated naevus is just as likely to be non-dysplastic as dysplastic. Multiple studies have shown that the most common melanoma-associated naevus is the bland (non-dysplastic) dermal naevus. The diagnosis of ‘dysplastic naevus’ is not relevant with respect to prognosis, the relevant prognostic factor being naevus-count (any naevus type).</li>
<li><b>What are the implications of this study for disease understanding and/or clinical care?</b> – Because there is ongoing uncertainty and confusion regarding best management of various grades of naevus-dysplasia, the diagnosis of ‘dysplastic naevus’ can unnecessarily complicate therapeutic decision-making for a large proportion of naevi. We present a diagnostic alternative of ‘borderline melanocytic lesion’ where any diagnostic uncertainty is clearly reported, and we demonstrate how this can halve the proportion of equivocal diagnoses and clarify therapeutic decision-making.</li>
</ul>
<p>To read the full article please <a href="https://onlinelibrary.wiley.com/doi/full/10.1002/jvc2.70144" target="_blank" rel="noopener">click here</a>.</p>
</div>
</section>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/uncategorised-hi/">UNCATEGORISED</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/a-diagnosis-of-dysplastic-naevus-has-no-clinical-relevance-and-unnecessarily-confounds-therapeutic-decision-making/">A Diagnosis of Dysplastic Naevus has no Clinical Relevance and Unnecessarily Confounds Therapeutic Decision-Making</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Risk Factor Number and Recurrence, Metastasis, and Disease-Related Death in Cutaneous Squamous Cell Carcinoma</title>
		<link>https://molemaxsystems.com/risk-factor-number-and-recurrence-metastasis-and-disease-related-death-in-cutaneous-squamous-cell-carcinoma/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Thu, 20 Mar 2025 00:49:40 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[dermatology research]]></category>
		<category><![CDATA[diagnostic skin cancer]]></category>
		<category><![CDATA[skin cancer]]></category>
		<category><![CDATA[Squamous Cell Carcinoma]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=7754</guid>

					<description><![CDATA[<p>Nina A. Ran, MD, MS; Emily E. Granger, MD; David G. Brodland, MD; et al JAMA Dermatol. Published online March 19, 2025. doi:10.1001/jamadermatol.2025.0128 Key Points Question  In cutaneous squamous cell carcinoma, how is the number of risk factors associated...</p>
<p>The post <a href="https://molemaxsystems.com/risk-factor-number-and-recurrence-metastasis-and-disease-related-death-in-cutaneous-squamous-cell-carcinoma/">Risk Factor Number and Recurrence, Metastasis, and Disease-Related Death in Cutaneous Squamous Cell Carcinoma</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><span class="wi-fullname brand-fg">Nina A. Ran, MD, MS</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Emily E. Granger, MD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">David G. Brodland, MD</span>; <span style="color: #000000;"><a class="meta-authors--etal td-u stats-meta-authors--etal" style="color: #000000;">et al</a></span></p>
<p><em><span class="meta-citation-journal-name">JAMA Dermatol. </span><span class="meta-citation">Published online March 19, 2025. doi:10.1001/jamadermatol.2025.0128</span></em></p>
<p><strong><span class="heading-text thm-col h3 cb section-type-keyPoints decorated-hed sb-sc ">Key Points</span></strong></p>
<p><strong>Question</strong>  In cutaneous squamous cell carcinoma, how is the number of risk factors associated with the risk of recurrence, metastasis, and disease related death?</p>
<p><strong>Findings</strong>  In this cohort study of 16 844 cases of cutaneous squamous cell carcinoma, tumors were stratified by the number of the following risk factors (0, 1, 2, 3, or 4): a diameter of 2 cm or larger, poorly differentiated histology, tumor extension beyond subcutaneous fat, and large caliber nerve invasion. Every incremental increase in the number of risk factors was associated with a greater risk of local recurrence, metastasis, and disease-related death.</p>
<p><strong>Meaning</strong>  The study results suggest that among individuals with cutaneous squamous cell carcinomas, the number of risk factors is an important indicator of risk.</p>
<p>To read the full article please <a href="https://jamanetwork.com/journals/jamadermatology/fullarticle/2831211?guestAccessKey=aff535d5-f612-43c9-a624-ed75974a26de&amp;utm_source=silverchair&amp;utm_medium=email&amp;utm_campaign=article_alert-jamadermatology&amp;utm_content=olf&amp;utm_term=031925&amp;adv=000004292862" target="_blank" rel="noopener">click here</a>.</p>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/uncategorised-hi/">UNCATEGORISED</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/risk-factor-number-and-recurrence-metastasis-and-disease-related-death-in-cutaneous-squamous-cell-carcinoma/">Risk Factor Number and Recurrence, Metastasis, and Disease-Related Death in Cutaneous Squamous Cell Carcinoma</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Balancing the risks and benefits of sun exposure: A revised position statement for Australian adults</title>
		<link>https://molemaxsystems.com/balancing-the-risks-and-benefits-of-sun-exposure-a-revised-position-statement-for-australian-adults/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Thu, 19 Sep 2024 00:44:19 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[dermatology research]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=7098</guid>

					<description><![CDATA[<p>Rachel E. Neale, Victoria Beedle, Peter R. Ebeling, Thomas Elliott, David Francis, Christian M. Girgis, Louisa Gordon, Monika Janda, Graeme Jones, Robyn M. Lucas, Rebecca S. Mason, Philip Keith Monnington,...</p>
<p>The post <a href="https://molemaxsystems.com/balancing-the-risks-and-benefits-of-sun-exposure-a-revised-position-statement-for-australian-adults/">Balancing the risks and benefits of sun exposure: A revised position statement for Australian adults</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Rachel E. Neale, Victoria Beedle, Peter R. Ebeling, Thomas Elliott, David Francis, Christian M. Girgis, Louisa Gordon, Monika Janda, Graeme Jones, Robyn M. Lucas, Rebecca S. Mason, Philip Keith Monnington, Julia Morahan, Georgia Paxton, Craig Sinclair, Stephen Shumack, Jane Smith, Ann R. Webb, David C. Whiteman</p>
<h3 class="section-title u-h4 u-margin-l-top u-margin-xs-bottom"><strong>Abstract</strong></h3>
<p>&nbsp;</p>
<div id="abssec0010">
<h3 id="sectitle0015" class="u-h4 u-margin-m-top u-margin-xs-bottom"><strong>Objective</strong></h3>
<p id="abspara0010">To describe the development of a new position statement regarding balancing the risks and benefits of sun exposure for Australian adults.</p>
<p>&nbsp;</p>
</div>
<div id="abssec0015">
<h3 id="sectitle0020" class="u-h4 u-margin-m-top u-margin-xs-bottom"><strong>Methods</strong></h3>
<p id="abspara0015">We conducted a Sun Exposure Summit in March 2021, with presentations from invited experts and a workshop including representation from academic, clinical, policy, and patient stakeholder organisations. The group considered advice about balancing the risks and benefits of sun exposure for Australian adults and developed a revised consensus position statement.</p>
<p>&nbsp;</p>
</div>
<div id="abssec0020">
<h3 id="sectitle0025" class="u-h4 u-margin-m-top u-margin-xs-bottom"><strong>Results</strong></h3>
<p id="abspara0020">The balance of risks and benefits of sun exposure is not the same for everybody. For people at very high risk of skin cancer, the risks of exposure likely outweigh the benefits; sun protection is essential. Conversely, people with deeply pigmented skin are at low risk of skin cancer but at high risk of <a class="topic-link" title="Learn more about vitamin D from ScienceDirect's AI-generated Topic Pages" href="https://www.sciencedirect.com/topics/medicine-and-dentistry/vitamin-d">vitamin D</a> deficiency; routine sun protection is not recommended. For those at intermediate risk of skin cancer, sun protection remains a priority, but individuals may obtain sufficient sun exposure to maintain adequate vitamin D status.</p>
<p>&nbsp;</p>
</div>
<div id="abssec0025">
<h3 id="sectitle0030" class="u-h4 u-margin-m-top u-margin-xs-bottom"><strong>Conclusions</strong></h3>
<p id="abspara0025">The new position statement provides sun exposure advice that explicitly recognises the differing needs of Australia’s diverse population.</p>
<p>To read the full article please <a href="https://www.sciencedirect.com/science/article/pii/S1326020023052949" target="_blank" rel="noopener">click here</a>.</p>
</div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/uncategorised-hi/">UNCATEGORISED</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/balancing-the-risks-and-benefits-of-sun-exposure-a-revised-position-statement-for-australian-adults/">Balancing the risks and benefits of sun exposure: A revised position statement for Australian adults</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Smart E-Skin Cancer Care in Europe During and After the Covid-19 Pandemic: A Multidisciplinary Expert Consensus</title>
		<link>https://molemaxsystems.com/smart-e-skin-cancer-care-in-europe-during-and-after-the-covid-19-pandemic-a-multidisciplinary-expert-consensus/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Wed, 06 Sep 2023 02:16:38 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[dermatology research]]></category>
		<category><![CDATA[dermoscopy]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com//?p=5403</guid>

					<description><![CDATA[<p>Josep Malvehy; Brigitte Dreno; Enric Barba; Thomas Dirschka; Emilio Fumero; Christian Greis; Girish Gupta; Francesco Lacarrubba; Giuseppe Micali; David Moreno; Giovanni Pellacani; Laura Sampietro-Colom; Alexander Stratigos; Susanna Puig https://doi.org/10.5826/dpc.1303a181 &#160; Introduction: Melanoma is the deadliest of all the skin cancers and its incidence is...</p>
<p>The post <a href="https://molemaxsystems.com/smart-e-skin-cancer-care-in-europe-during-and-after-the-covid-19-pandemic-a-multidisciplinary-expert-consensus/">Smart E-Skin Cancer Care in Europe During and After the Covid-19 Pandemic: A Multidisciplinary Expert Consensus</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<figure class="wp-block-table">
<table>
<tbody>
<tr>
<td>Josep Malvehy; Brigitte Dreno; Enric Barba; Thomas Dirschka; Emilio Fumero; Christian Greis; Girish Gupta; Francesco Lacarrubba; Giuseppe Micali; David Moreno; Giovanni Pellacani; Laura Sampietro-Colom; Alexander Stratigos; Susanna Puig</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption"><a href="https://doi.org/10.5826/dpc.1303a181">https://doi.org/10.5826/dpc.1303a181</a></figcaption>
</figure>



<p class="wp-block-paragraph">&nbsp;</p>



<p class="wp-block-paragraph"><strong>Introduction: </strong>Melanoma is the deadliest of all the skin cancers and its incidence is increasing every year in Europe. Patients with melanoma often present late to the specialist and treatment is delayed for many reasons (delay in patient consultation, misdiagnosis by general practitioners, and/or limited access to dermatologists). Beyond this, there are significant inequalities in skin cancer between population groups within the same country and between countries across Europe. The emergence of the COVID-19 pandemic only aggravated these health deficiencies.</p>



<p class="wp-block-paragraph"><a href="https://dpcj.org/index.php/dpc/article/view/2877">Click her</a><a href="https://dpcj.org/index.php/dpc/article/view/2877" target="_blank" rel="noreferrer noopener">e</a> to read the full article.</p>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/uncategorised-hi/">UNCATEGORISED</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/smart-e-skin-cancer-care-in-europe-during-and-after-the-covid-19-pandemic-a-multidisciplinary-expert-consensus/">Smart E-Skin Cancer Care in Europe During and After the Covid-19 Pandemic: A Multidisciplinary Expert Consensus</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Extrafacial Lentigo Maligna: A Clinical And Dermoscopic Analysis According to Localization</title>
		<link>https://molemaxsystems.com/extrafacial-lentigo-maligna-a-clinical-and-dermoscopic-analysis-according-to-localization/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Thu, 28 Jul 2022 03:34:57 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[dermatology]]></category>
		<category><![CDATA[dermatology research]]></category>
		<category><![CDATA[dermoscopic]]></category>
		<category><![CDATA[lentigo maligna]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com//?p=3242</guid>

					<description><![CDATA[<p>National Library of Medicine &#8211; published January 2022 Gabriel Salerni , Emilia Cohen-Sabban , Horacio Cabo &#160; &#160; Introduction: Whether extrafacial lentigo maligna (EFLM) differs clinically and/or dermoscopically according to location has not been analyzed...</p>
<p>The post <a href="https://molemaxsystems.com/extrafacial-lentigo-maligna-a-clinical-and-dermoscopic-analysis-according-to-localization/">Extrafacial Lentigo Maligna: A Clinical And Dermoscopic Analysis According to Localization</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">National Library of Medicine &#8211; published January 2022</p>



<p class="wp-block-paragraph"><strong>Gabriel Salerni<sup> </sup>, Emilia Cohen-Sabban<sup> </sup>, Horacio Cabo</strong></p>


<hr class="wp-block-separator" />


<p class="wp-block-paragraph">&nbsp;</p>



<p class="wp-block-paragraph">&nbsp;</p>



<p class="wp-block-paragraph"><strong>Introduction: </strong>Whether extrafacial lentigo maligna (EFLM) differs clinically and/or dermoscopically according to location has not been analyzed in depth.</p>



<p class="wp-block-paragraph"><strong>Objectives: </strong>To evaluate clinical and dermoscopic characteristics regarding different localization in a series of EFLM.</p>



<p class="wp-block-paragraph"><strong>Methods: </strong>We conducted a retrospective analysis of clinical and dermoscopic characteristics of 69 histologically proven EFLM retrieved from the database of two private institutions.</p>



<p class="wp-block-paragraph"><strong>Results</strong>: Of the 69 EFLM included in the study, 25 (36.2%) were located in posterior trunk (PT), 16 (23.2%) in anterior trunk (AT), 15 (21%) in upper extremities (UE), and 13 (18.8%) in lower extremities (LE). Mean diameter among localization were as follows: 14.3 mm in PT, 11.8 mm in AT, 14 mm in UE, and 10 mm in LE (p 0.44). The most frequent dermoscopic criteria were angulated lines and tan structureless areas (70%), followed by atypical pigment network (60%), both with similar distribution among groups. Angulated lines pattern was the most frequent global pattern, observed in 55% of cases. Tan structureless/granularity pattern and patchy peripheral pigmented islands pattern were seen in 15.6% and 11.6% cases, respectively. No statistically significant differences were observed in the distribution of global dermoscopic pattern in the different localizations. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824700/">T</a><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824700/" target="_blank" rel="noreferrer noopener">o read more click here</a></p>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/uncategorised-hi/">UNCATEGORISED</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/extrafacial-lentigo-maligna-a-clinical-and-dermoscopic-analysis-according-to-localization/">Extrafacial Lentigo Maligna: A Clinical And Dermoscopic Analysis According to Localization</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
